All articles tagged with #study results
Insmed Incorporated's stock surged by up to 110% following positive study results for a drug treating bronchiectasis, a chronic lung condition. Analysts are optimistic about the company's future, with plans to file for U.S. market clearance and potential applications for other diseases.
Tempest Therapeutics (TPST) stock is up 325% as the clinical-stage oncology company prepares to release updated study results from a Phase 1b/2 combination study of TPST-1120 with atezolizumab and bevacizumab as a first-line treatment for hepatocellular carcinoma. Investors are eagerly awaiting the results, with heavy trading volume indicating high expectations. If the study fails to deliver positive news, TPST stock may lose the momentum it has gained.